Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin.
Aerobic glycolysis
Hexokinase
Metabolism reprogramming
Metformin
Nicotinamide adenine dinucleotide phosphate
Oxidative phosphorylation
Journal
Cancer & metabolism
ISSN: 2049-3002
Titre abrégé: Cancer Metab
Pays: England
ID NLM: 101607582
Informations de publication
Date de publication:
11 Dec 2021
11 Dec 2021
Historique:
received:
04
06
2021
accepted:
16
11
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
14
12
2021
Statut:
epublish
Résumé
Hexokinases (HKs) are well-studied enzymes catalyzing the first step of glycolysis. However, non-canonical regulatory roles of HKs are still incompletely understood. Here, we hypothesized that HKs comprise one of the missing links between high-dose metformin and the inhibition of the respiratory chain in cancer. We tested the isoenzyme-specific regulatory roles of HKs in ovarian cancer cells by examining the effects of the deletions of HK1 and HK2 in TOV-112D ovarian adenocarcinoma cells. We reverted these effects by re-introducing wild-type HK1 and HK2, and we compared the HK1 revertant with the knock-in of catalytically dead HK1 p.D656A. We subjected these cells to a battery of metabolic and proliferation assays and targeted GC×GC-MS metabolomics. We found that the HK1 depletion (but not the HK2 depletion) sensitized ovarian cancer cells to high-dose metformin during glucose starvation. We confirmed that this newly uncovered role of HK1 is glycolysis-independent by the introduction of the catalytically dead HK1. The expression of catalytically dead HK1 stimulated similar changes in levels of TCA intermediates, aspartate and cysteine, and in glutamate as were induced by the HK2 deletion. In contrast, HK1 deletion increased the levels of branched amino acids; this effect was completely eliminated by the expression of catalytically dead HK1. Furthermore, HK1 revertants but not HK2 revertants caused a strong increase of NADPH/NADP ratios independently on the presence of glucose or metformin. The HK1 deletion (but not HK2 deletion) suppressed the growth of xenotransplanted ovarian cancer cells and nearly abolished the tumor growth when the mice were fed the glucose-free diet. We provided the evidence that HK1 is involved in the so far unknown glycolysis-independent HK1-metformin axis and influences metabolism even in glucose-free conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Hexokinases (HKs) are well-studied enzymes catalyzing the first step of glycolysis. However, non-canonical regulatory roles of HKs are still incompletely understood. Here, we hypothesized that HKs comprise one of the missing links between high-dose metformin and the inhibition of the respiratory chain in cancer.
METHODS
METHODS
We tested the isoenzyme-specific regulatory roles of HKs in ovarian cancer cells by examining the effects of the deletions of HK1 and HK2 in TOV-112D ovarian adenocarcinoma cells. We reverted these effects by re-introducing wild-type HK1 and HK2, and we compared the HK1 revertant with the knock-in of catalytically dead HK1 p.D656A. We subjected these cells to a battery of metabolic and proliferation assays and targeted GC×GC-MS metabolomics.
RESULTS
RESULTS
We found that the HK1 depletion (but not the HK2 depletion) sensitized ovarian cancer cells to high-dose metformin during glucose starvation. We confirmed that this newly uncovered role of HK1 is glycolysis-independent by the introduction of the catalytically dead HK1. The expression of catalytically dead HK1 stimulated similar changes in levels of TCA intermediates, aspartate and cysteine, and in glutamate as were induced by the HK2 deletion. In contrast, HK1 deletion increased the levels of branched amino acids; this effect was completely eliminated by the expression of catalytically dead HK1. Furthermore, HK1 revertants but not HK2 revertants caused a strong increase of NADPH/NADP ratios independently on the presence of glucose or metformin. The HK1 deletion (but not HK2 deletion) suppressed the growth of xenotransplanted ovarian cancer cells and nearly abolished the tumor growth when the mice were fed the glucose-free diet.
CONCLUSIONS
CONCLUSIONS
We provided the evidence that HK1 is involved in the so far unknown glycolysis-independent HK1-metformin axis and influences metabolism even in glucose-free conditions.
Identifiants
pubmed: 34895333
doi: 10.1186/s40170-021-00277-2
pii: 10.1186/s40170-021-00277-2
pmc: PMC8666047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Subventions
Organisme : Grantová Agentura, Univerzita Karlova
ID : 324421
Organisme : Grantová Agentura, Univerzita Karlova
ID : 1428218
Organisme : Univerzita Karlova v Praze
ID : 260531/SVV/2020
Informations de copyright
© 2021. The Author(s).
Références
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Cell Metab. 2016 Mar 8;23(3):517-28
pubmed: 26853747
Cancer Res. 2012 Dec 1;72(23):6257-67
pubmed: 23041548
Nat Methods. 2015 Dec;12(12):1143-9
pubmed: 26501517
Antioxid Redox Signal. 2019 Jan 20;30(3):415-442
pubmed: 29742915
Cancer Metab. 2014 Aug 28;2:12
pubmed: 25184038
PLoS Biol. 2018 Aug 27;16(8):e2004624
pubmed: 30148842
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7114-8
pubmed: 3174623
J Cell Biol. 1988 Dec;107(6 Pt 2):2729-36
pubmed: 2462567
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Nature. 2018 Aug;560(7719):499-503
pubmed: 30051890
Nature. 2019 Dec;576(7787):482-486
pubmed: 31827279
BMJ. 2015 Sep 01;351:h4443
pubmed: 26328593
Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
pubmed: 20947488
Sci Rep. 2013;3:2070
pubmed: 23797762
Cell Metab. 2018 Nov 6;28(5):706-720.e6
pubmed: 30122555
Nat Commun. 2018 Jan 31;9(1):446
pubmed: 29386513
J Biol Chem. 2002 Mar 1;277(9):7610-8
pubmed: 11751859
J Clin Invest. 2001 Oct;108(8):1167-74
pubmed: 11602624
Cancer Res. 2019 May 15;79(10):2748-2760
pubmed: 30885978
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Nat Protoc. 2012 Apr 12;7(5):872-81
pubmed: 22498707
Trends Biochem Sci. 2005 Mar;30(3):142-50
pubmed: 15752986
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1518-23
pubmed: 22233811
Front Oncol. 2020 Nov 02;10:1703
pubmed: 33224868
Dis Model Mech. 2018 Aug 7;11(8):
pubmed: 30104199
Oncogene. 2006 Aug 7;25(34):4777-86
pubmed: 16892090
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Trends Biochem Sci. 2016 Aug;41(8):712-730
pubmed: 27345518
Mol Cell Biol. 2004 Jul;24(13):5923-36
pubmed: 15199147
Nat Biotechnol. 2014 Sep;32(9):941-6
pubmed: 24952903
Cell. 2016 Jul 28;166(3):624-636
pubmed: 27374331
Mol Syst Biol. 2017 Feb 15;13(2):914
pubmed: 28202506
Redox Biol. 2014;2:963-70
pubmed: 25460731
PLoS Biol. 2015 Dec 01;13(12):e1002309
pubmed: 26625127
Cell Metab. 2015 Feb 3;21(2):159-162
pubmed: 25651170
BMC Cancer. 2008 Apr 30;8:122
pubmed: 18447912
Cancer Prev Res (Phila). 2009 Jun;2(6):557-65
pubmed: 19470786
Cell Metab. 2016 Nov 8;24(5):728-739
pubmed: 27746051
Nature. 2014 Jun 26;510(7506):542-6
pubmed: 24847880
Oncotarget. 2018 Apr 10;9(27):18949-18969
pubmed: 29721175
Elife. 2017 Aug 15;6:
pubmed: 28826492
PLoS One. 2011 Mar 09;6(3):e17674
pubmed: 21408025
Trends Biochem Sci. 2010 Aug;35(8):423-6
pubmed: 20554447
BMC Cancer. 2018 Jun 5;18(1):636
pubmed: 29866066
BMC Cancer. 2016 May 13;16:310
pubmed: 27178315
Biochem J. 2000 Jun 15;348 Pt 3:607-14
pubmed: 10839993
Oncogene. 2017 Jan 26;36(4):525-533
pubmed: 27375016
Nature. 2013 Feb 14;494(7436):256-60
pubmed: 23292513
Cell Metab. 2020 Oct 6;32(4):676-688.e4
pubmed: 32791100
PLoS One. 2018 Feb 20;13(2):e0193182
pubmed: 29462198
J Exp Biol. 2003 Jun;206(Pt 12):2049-57
pubmed: 12756287
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Structure. 1998 Jan 15;6(1):39-50
pubmed: 9493266
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20491-6
pubmed: 23185017
Nat Metab. 2019 Mar;1:404-415
pubmed: 31058257
Obstet Gynecol. 2012 Jan;119(1):61-7
pubmed: 22183212
Front Mol Biosci. 2021 Jun 09;8:701975
pubmed: 34235183
Nucleic Acids Res. 2019 Jul 2;47(W1):W171-W174
pubmed: 31106371
Biochim Biophys Acta. 1998 Mar 5;1401(3):242-64
pubmed: 9540816
Trends Endocrinol Metab. 2015 Dec;26(12):746-757
pubmed: 26520658
Science. 2005 Dec 9;310(5754):1642-6
pubmed: 16308421
Front Oncol. 2020 Jan 31;10:52
pubmed: 32083006
Cell Metab. 2019 Jan 8;29(1):156-173.e10
pubmed: 30244973
Gynecol Oncol. 2016 Oct;143(1):3-15
pubmed: 27650684
J Biol Chem. 2000 Jan 7;275(1):223-8
pubmed: 10617608
Nat Protoc. 2006;1(6):2643-9
pubmed: 17406520